# A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

> **NCT07570173** · PHASE2,PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 340 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** MK-1045
- **BIOLOGICAL:** Blinatumomab
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Dexamethasone
- **DRUG:** Tocilizumab
- **DRUG:** Siltuximab
- **DRUG:** Avtozma
- **DRUG:** Tyenne

## Key facts

- **NCT ID:** NCT07570173
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-22
- **Primary completion:** 2029-02-10
- **Final completion:** 2029-10-02
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570173, "A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)". Retrieved via MORVS 2026-10-31 from https://api.morvs.ai/clinical/NCT07570173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*